Q1 Earnings Forecast for HALO Issued By Leerink Partnrs

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Halozyme Therapeutics in a research report issued to clients and investors on Sunday, January 12th. Leerink Partnrs analyst D. Risinger forecasts that the biopharmaceutical company will post earnings per share of $0.93 for the quarter. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $3.80 per share. Leerink Partnrs also issued estimates for Halozyme Therapeutics' Q2 2025 earnings at $1.04 EPS, Q3 2025 earnings at $1.41 EPS and FY2029 earnings at $8.16 EPS.

A number of other research analysts have also recently commented on the stock. Wells Fargo & Company reduced their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday. HC Wainwright raised their target price on Halozyme Therapeutics from $68.00 to $70.00 and gave the company a "buy" rating in a research note on Friday. JMP Securities boosted their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a research note on Friday, November 1st. JPMorgan Chase & Co. lowered Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and raised their price objective for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. Finally, Piper Sandler upped their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $60.89.

Halozyme Therapeutics Stock Down 0.6 %

Halozyme Therapeutics stock traded down $0.31 during midday trading on Tuesday, hitting $53.83. 1,360,875 shares of the company were exchanged, compared to its average volume of 1,759,269. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The company's fifty day moving average price is $50.05 and its 200-day moving average price is $54.05. The company has a market cap of $6.85 billion, a PE ratio of 17.82, a price-to-earnings-growth ratio of 0.44 and a beta of 1.24.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of the company's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the transaction, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. This represents a 18.65 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 2.40% of the company's stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Argent Capital Management LLC raised its stake in shares of Halozyme Therapeutics by 35.1% during the fourth quarter. Argent Capital Management LLC now owns 12,841 shares of the biopharmaceutical company's stock valued at $614,000 after purchasing an additional 3,339 shares in the last quarter. Outlook Wealth Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter worth approximately $355,000. Redhawk Wealth Advisors Inc. boosted its holdings in shares of Halozyme Therapeutics by 3.4% in the fourth quarter. Redhawk Wealth Advisors Inc. now owns 38,035 shares of the biopharmaceutical company's stock valued at $1,818,000 after acquiring an additional 1,267 shares in the last quarter. Park Avenue Securities LLC increased its stake in shares of Halozyme Therapeutics by 6.9% during the fourth quarter. Park Avenue Securities LLC now owns 12,439 shares of the biopharmaceutical company's stock valued at $595,000 after acquiring an additional 801 shares during the period. Finally, Tealwood Asset Management Inc. raised its holdings in Halozyme Therapeutics by 19.7% during the fourth quarter. Tealwood Asset Management Inc. now owns 52,813 shares of the biopharmaceutical company's stock worth $2,525,000 after purchasing an additional 8,694 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.